179 related articles for article (PubMed ID: 3717812)
1. High-dose glucocorticoid treatment of resistant myeloma.
Alexanian R; Barlogie B; Dixon D
Ann Intern Med; 1986 Jul; 105(1):8-11. PubMed ID: 3717812
[TBL] [Abstract][Full Text] [Related]
2. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
Barlogie B; Smith L; Alexanian R
N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971
[TBL] [Abstract][Full Text] [Related]
4. Treatment strategies for plasma cell myeloma.
Smith L; Alexanian R
CA Cancer J Clin; 1985; 35(4):214-20. PubMed ID: 3926257
[No Abstract] [Full Text] [Related]
5. Treatment of refractory multiple myeloma with the vincristine-adriamycin-dexamethasone (VAD) regimen.
Stenzinger W; Blömker A; Hiddemann W; van de Loo J
Blut; 1990; 61(2-3):55-9. PubMed ID: 2207342
[TBL] [Abstract][Full Text] [Related]
6. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group.
Browman GP; Belch A; Skillings J; Wilson K; Bergsagel D; Johnston D; Pater JL
Br J Haematol; 1992 Nov; 82(3):555-9. PubMed ID: 1486035
[TBL] [Abstract][Full Text] [Related]
7. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).
Adam Z; Elbl L; Vorlicek J; Hájek R; Hájek D; Hejlová N; Králová E; Novotná H
Acta Med Austriaca; 1994; 21(4):111-5. PubMed ID: 7871966
[TBL] [Abstract][Full Text] [Related]
8. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
9. [Comparative evaluation of treatment results in advanced multiple myeloma with the help of polychemotherapy with vincristine, doxorubicin, dexamethasone (VAD) or only with dexamethasone].
Hansz J; Włodarczyk M; Psuja P
Acta Haematol Pol; 1992; 23(4):277-84. PubMed ID: 1293910
[TBL] [Abstract][Full Text] [Related]
10. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
Dalton WS; Grogan TM; Meltzer PS; Scheper RJ; Durie BG; Taylor CW; Miller TP; Salmon SE
J Clin Oncol; 1989 Apr; 7(4):415-24. PubMed ID: 2564428
[TBL] [Abstract][Full Text] [Related]
11. Primary dexamethasone treatment of multiple myeloma.
Alexanian R; Dimopoulos MA; Delasalle K; Barlogie B
Blood; 1992 Aug; 80(4):887-90. PubMed ID: 1498331
[TBL] [Abstract][Full Text] [Related]
12. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON.
Sonneveld P; Durie BG; Lokhorst HM; Marie JP; Solbu G; Suciu S; Zittoun R; Löwenberg B; Nooter K
Lancet; 1992 Aug; 340(8814):255-9. PubMed ID: 1353189
[TBL] [Abstract][Full Text] [Related]
13. VAD-cyclosporine therapy for VAD-resistant multiple myeloma.
Weber D; Dimopoulos M; Sinicrope F; Alexanian R
Leuk Lymphoma; 1995 Sep; 19(1-2):159-63. PubMed ID: 8574163
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol.
Giles FJ; Wickham NR; Rapoport BL; Somlo G; Lim SW; Shan J; Lynott AM
Am J Hematol; 2000 Mar; 63(3):125-30. PubMed ID: 10679801
[TBL] [Abstract][Full Text] [Related]
15. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.
Dimopoulos MA; Pouli A; Zervas K; Grigoraki V; Symeonidis A; Repoussis P; Mitsouli C; Papanastasiou C; Margaritis D; Tokmaktsis A; Katodritou I; Kokkini G; Terpos E; Vyniou N; Tzilianos M; Chatzivassili A; Kyrtsonis MC; Panayiotidis P; Maniatis A;
Ann Oncol; 2003 Jul; 14(7):1039-44. PubMed ID: 12853344
[TBL] [Abstract][Full Text] [Related]
16. Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data.
Tsiara SN; Kapsali E; Christou L; Panteli A; Pritsivelis N; Bourantas KL
Eur J Haematol; 2000 Aug; 65(2):118-22. PubMed ID: 10966172
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of resistant multiple myeloma with vincristine, adriamycin and dexamethasone (VAD).
Maniatis A; Stamatellou M; Papanastasiou K
Chemioterapia; 1987 Jun; 6(2 Suppl):727-8. PubMed ID: 3509532
[No Abstract] [Full Text] [Related]
18. Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.
Barlogie B; Velasquez WS; Alexanian R; Cabanillas F
J Clin Oncol; 1989 Oct; 7(10):1514-7. PubMed ID: 2778481
[TBL] [Abstract][Full Text] [Related]
19. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
[TBL] [Abstract][Full Text] [Related]
20. Bolus vincristine and epirubicin with cyclophosphamide and dexamethasone (VECD) as induction and salvage treatment in multiple myeloma.
Fosså A; Muer M; Kasper C; Welt A; Seeber S; Nowrousian MR
Leukemia; 1998 Mar; 12(3):422-6. PubMed ID: 9529138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
